HK Stock Market Move | VISEN PHARMA-B (02561) rose by more than 7% during trading hours. The company's core product, Longpei Growth Hormone, is about to be approved.

09:49 01/12/2025

Weisheng Pharmaceutical Industry-B (02561) rose more than 7% during trading hours, as of the time of publication, it was up 3.64% to 31.88 Hong Kong dollars.

VISEN PHARMA-B (02561) surged more than 7% during trading hours, and as of press time, it was up 3.64% at 31.88 Hong Kong dollars. In terms of news, Anhui Anke Biotechnology recently disclosed progress in cooperation, with the Longping plant growth hormone, co-developed with Weisheng Pharmaceuticals, set to be approved soon. According to reports, on July 14, Anhui Anke Biotechnology announced that the company had signed a strategic cooperation framework agreement with Weisheng Pharmaceuticals to jointly promote the popularization of Longping plant growth hormone in the Chinese market. Weisheng Pharmaceuticals' core product, Longping plant growth hormone, had its market application accepted by the China National Medical Products Administration in March 2024, with approval for market listing expected in the second half of 2025.

HK Stock Market Move | LYGEND RESOURCE(02245) surged more than 5%, Indonesian nickel smelters may be warned to stop production, the company has potential for future expansion in the industry chain layout.

CMSC Global: maintains target price of HK$139 for MEITUAN-W (03690) with a rating of "hold"

HK Stock Market Move | YUHUA EDU (06169) rose nearly 4%, with the annual net profit increasing by 1.33 times to 930 million yuan.

CMSC Global: maintains target price of HK$139 for MEITUAN-W (03690) with a rating of "hold"

HK Stock Market Move | YUHUA EDU (06169) rose nearly 4%, with the annual net profit increasing by 1.33 times to 930 million yuan.